Literature DB >> 8113827

A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies.

T P van Staa1, L Abenhaim, H Leufkens.   

Abstract

This paper considers the effects of the time-window design on the validity of risk estimates in record linkage studies. A time-window constitutes the number of exposure days assigned to each prescription, often fixed time-intervals. Prescription information was drawn from 36 Dutch pharmacies. Persons, assuming full compliance to the dosage regimen, used NSAIDs during 58% of the 30 day window time (31% with 90 day window). This proportion ranged from 51 to 81% for different NSAIDs; from 75% for elderly to 35% for younger persons. We observed with longer windows a substantive attenuation of incidence rates of peptic ulcer therapy. Simulations also showed that the assignment of equal windows to groups with different durations of drug use can bias risk comparisons, either away from the null or towards the null. We concluded that the choice of prescription time-windows can influence the estimates of exposure risks. Time-windows should cover the period with potential excess risk and be validated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113827     DOI: 10.1016/0895-4356(94)90023-x

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  16 in total

1.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

2.  Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses.

Authors:  R T Koopmans; J M van Rossum; H J van den Hoogen; Y A Hekster; M A Willekens-Bogaers; C van Weel
Journal:  Pharm World Sci       Date:  1996-01

3.  Evidence of sample use among new users of statins: implications for pharmacoepidemiology.

Authors:  Xiaojuan Li; Til Stürmer; M Alan Brookhart
Journal:  Med Care       Date:  2014-09       Impact factor: 2.983

4.  The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies.

Authors:  Elisabetta Patorno; Joshua J Gagne; Christine Y Lu; Kevin Haynes; Andrew T Sterrett; Jason Roy; Xingmei Wang; Marsha A Raebel
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

5.  Methods for constructing treatment episodes and impact on exposure-outcome associations.

Authors:  Laura Pazzagli; Lena Brandt; Marie Linder; David Myers; Panagiotis Mavros; Morten Andersen; Shahram Bahmanyar
Journal:  Eur J Clin Pharmacol       Date:  2019-11-22       Impact factor: 2.953

Review 6.  Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.

Authors:  Thomas M Caparrotta; James W Dear; Helen M Colhoun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

7.  Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark.

Authors:  Lene Mellemkjaer; William J Blot; Henrik Toft Sørensen; Lars Thomassen; Joseph K McLaughlin; Gunnar Lauge Nielsen; Jørgen H Olsen
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

8.  Comparing the Sensitivities of Measures of Adherence to Antihypertensive Drugs Using Korean National Health Insurance Claims Data.

Authors:  Eunjung Choo; Minji Jung; Jaekyu Shin; Sukhyang Lee
Journal:  Patient Prefer Adherence       Date:  2021-08-08       Impact factor: 2.711

9.  Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study.

Authors:  S I Sjahid; P D van der Linden; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

10.  Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Authors:  Lisandro D Colantonio; Shia T Kent; Meredith L Kilgore; Elizabeth Delzell; Jeffrey R Curtis; George Howard; Monika M Safford; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.